Company Overview and News

Fortis jumps 3% as Hero-Burman combine raises offer price

5h thehindubusinessline
Fortis, which runs about 30 hospitals across India, has become the target of a takeover battle, with Malaysia's IHH Healthcare Bhd, local rival Manipal Health Enterprises Pvt Ltd and China's Fosun International Ltd vying for the cash-strapped company.

Fortis Healthcare gets improved offer from Hero Enterprise, Burman Family

7h livemint
Fortis Healthcare Ltd said on Thursday it had received an improved binding offer worth Rs1,500 crore from Hero Enterprise Investment Office and Burman Family Office. The proposal is higher than their last week’s offer of Rs1,250 crore.

Company News: Jammu and Kashmir Bank

18h thehindubusinessline
Housing Development and Infrastructure has offered to settle its outstanding dues with Jammu and Kashmir Bank by May 2 after the lender filed an insolvency plea against the company before the National Company Law Tribunal. According to a Cogencis report, in January, the company had offered a one-time settlement to the bank and had agreed to pay ₹280 crore by March 31, the lender’s lawyer told the tribunal.

Will TCS better street expectations?

20h thehindubusinessline
Tata Consultancy Services will declare results for Q4 and full-year ended March 2018 on Thursday. Though Infosys posted results on expected lines, its shares fell close to 4 per cent since the results, as the company lowered its margin guidance to 22-24 per cent for FY19 from 23-25 per cent in FY18. Most analysts expect TCS’ results to be better than Infosys. Analysts also expect the largest market-cap company to announce a margin guidance of over 25 per cent.

Dynamatic Tech: On radar thanks to tie-up

20h thehindubusinessline
Dynamatic Technologies has signed a memorandum of understanding with Daher Aerospace, a global aerospace company from France. The MoU facilitates exploring possibilities of partnering together to add potential value in the global aerospace realm through collaborated efforts. Shareholders will closely track the development. The company had reported a profit of ₹3.47 crore on revenues of ₹150.48 crore in the December 2017 quarter.

IndusInd Bank, RPower results on Thursday

20h thehindubusinessline
Over half-a-dozen companies will declare their quarterly and full-year results for the period ended March 2018 on Thursday. These are Bharat Seats, Cyient, IndusInd Bank, Infomedia Press, Mahindra CIE Automotive, Reliance Power, RS Software (India) and Shree Digvijay Cement Company. Focus will be on IndusInd Bank, a bank that has shown consistent growth in net profit over the years. Eyes will be on the NPA figure that the bank will disclose.

Company News: Bio Green Papers

20h thehindubusinessline
The board of directors of Bio Green Papers has considered and decided to acquire 49 per cent stake in Challenger Crop Care Technologies Pvt Ltd (CCCTPL) through a share swap, subject to approvals from statutory agencies. The board decided to convert the unsecured loans amounting to ₹2 crore into preference shares at a coupon rate. The board also decided to increase the authorised capital of the company, subject to approvals from statutory agencies.

Company News: Cera Sanitaryware

20h thehindubusinessline
The board of directors of Cera Sanitaryware has approved the re-classification of shares held by Madhusudan Holdings and Late Ganga Somany from existing promoters/ promoter group shareholding to ‘public shareholding’. Just 28,000 shares or 0.22 per cent were held by Ganga Somany at the end of March 2018 and 7,500 shares (0.06 per cent) by Madhusudan Holdings. Shares of Cera Sanitaryware slipped 0.3 per cent at ₹3,208.

Sensex snaps 9-day winning streak on correction in banks, but ITC caps losses

2018-04-18 moneycontrol
The market fell for the first time in last 10 consecutive sessions, closing marginally in the red on Wednesday weighed by extended sell off in banks in last hour of trade. However, the rally in index heavyweight ITC capped losses.

Closing Bell: Sensex, Nifty close lower; banks drag but FMCG stocks support

2018-04-18 moneycontrol
3:30 pm Market Closing: Benchmark indices closed lower for the first time in last 10 consecutive sessions, dragged by banks. However, the upside in ITC capped losses.

Market Live: Sensex erases gains, Nifty below 10,550; banks under pressure

2018-04-18 moneycontrol
1:55 pm Earnings: Mastek's Q4 consolidated net profit increased to Rs 19.4 crore from Rs 18.4 crore and revenue grew by 6.8 percent to Rs 223.7 crore on sequential basis.

Market Update: FMCG, realty space outperforms led by Godrej Properties, ITC; Infosys, ICICI most active

2018-04-18 moneycontrol
The Indian equity market was trading flat on Wednesday afternoon with the Nifty marginally up and was trading at 10,554 while the Sensex was up 26 points or 0.08 percent.

Market Live: Sensex extends gains, Nifty inches towards 10,600; ITC leads

2018-04-18 moneycontrol
1:18 pm Market Update: Benchmark indices extended gains in afternoon trade, with the Nifty inching towards 10,600 levels on hopes of strong earnings growth.

Market Live: Nifty holds 10,550; FMCG index up 2%, Bharti Group stocks gain

2018-04-18 moneycontrol
12:55 pm Earnings Outlook: "We are looking at Sensex earnings. In Q4, earnings will grow in the range of 13-14 percent, which will be double digit growth after a long time. Partially, this will be due to low base of Q4 last year and the other due to better earnings of global commodity companies, be it energy or metals. That will aid overall growth,” Gaurav Dua, Head of Research, Sharekhan told Moneycontrol.

Nikkei hits 7-week high as earnings hopes buoy Wall Street

2018-04-18 thehindubusinessline
The Nikkei rose 1.2 per cent to 22,109.48 in midmorning trade, after hitting a high of 22,136.21, its strongest level since February 28. - Reuters

Related Articles

RDHL: Redhill Biopharma Ltd (OTC:REDIF) Analysis and Research Report

2018-04-18 - Asif

History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...

SCYX: SCYNEXIS Analysis and Research Report

2018-04-16 - Asif

Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...

ENRT: Enertopia Corp (CNSX:TOP) Analysis and Research Report

2018-04-16 - Asif

Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...

FB: Facebook Analysis and Research Report

2018-04-15 - Asif

Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...

VSTM: Verastem Analysis and Research Report

2018-04-12 - Asif

Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...

CUSIP: 006297356